LY3549492
DrugAdministered orally
NCT Number: NCT06869018
The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it.
The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 1
Hakata Clinic, Fukuoka, Japan
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Part A:
Part B:
Exclusion criteria
Administered orally
Administered orally
Time frame: Day 1 Through Day 127
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Day 1 Through Day 127
PK: AUC of LY3549492
Time frame: Day 1 Through Day 127
PK: Cmax of LY3549492
Time frame: Day 1 Through Day 127
PD: Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Day 1 Through Day 127
PD: Change from Baseline in Body Weight
Eli Lilly and Company
Industry
A Randomized, Investigator- and Participant-blinded, Multiple-ascending Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus and Healthy Japanese Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04262128
Behavior, Cardiovascular Diseases
Aurora, Colorado, United States
View Trial DetailsNCT05563090
Cardiovascular Diseases, Diabete Mellitus
Singapore
View Trial DetailsNCT01507285
Diabetes, Diabetes Mellitus
Manchester, United Kingdom
View Trial DetailsNCT01686945
Diabetes, Diabetes Mellitus
Berlin, Germany
View Trial Details